# A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

> **NCT04712396** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 11 (actual)

## Conditions studied

- Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT04712396
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-03-25
- **Final completion:** 2021-03-25
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712396, "A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04712396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*